Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey Conn

Showing results (21-30 of 416) with videos related to

Pageof 42
Sort By:
Current Opinion in Pharmacology|February 28, 2018
The therapeutic potential of metabotropic glutamate receptor modulation for schizophreniaBranden J Stansley, P Jeffrey Conn
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Direct and indirect modulation of the N-methyl D-aspartate receptorM J Marino, P Jeffrey Conn
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
mGluR7's lucky numberP Jeffrey Conn, Colleen M Niswender
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 25, 2008
Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settingsP Jeffrey Conn, Bryan L Roth
Annual Review of Pharmacology and Toxicology|January 9, 2010
Metabotropic glutamate receptors: physiology, pharmacology, and diseaseColleen M Niswender, P Jeffrey Conn
The International Journal of Neuropsychopharmacology|December 10, 2015
Neurobiological Insights from mGlu Receptor Allosteric ModulationDaniel E O'Brien, P Jeffrey Conn
ACS Chemical Neuroscience|October 23, 2018
Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent ModelsSamantha E Yohn, P Jeffrey Conn
Pharmacological Reviews|June 16, 2022
Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric DiseaseDeborah J Luessen, P Jeffrey Conn
Neuropharmacology|September 13, 2017
Positive allosteric modulation of M<sub>1</sub> and M<sub>4</sub> muscarinic receptors as potential therapeutic treatments for schizophreniaSamantha E Yohn, P Jeffrey Conn
Neuropharmacology|July 16, 2008
Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cellsDouglas J Sheffler, P Jeffrey Conn
Pageof 42

Showing results (21-30 of 416) with videos related to

Sort By:
Pageof 42
Current Opinion in Pharmacology|February 28, 2018
The therapeutic potential of metabotropic glutamate receptor modulation for schizophreniaBranden J Stansley, P Jeffrey Conn
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Direct and indirect modulation of the N-methyl D-aspartate receptorM J Marino, P Jeffrey Conn
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
mGluR7's lucky numberP Jeffrey Conn, Colleen M Niswender
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 25, 2008
Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settingsP Jeffrey Conn, Bryan L Roth
Annual Review of Pharmacology and Toxicology|January 9, 2010
Metabotropic glutamate receptors: physiology, pharmacology, and diseaseColleen M Niswender, P Jeffrey Conn
The International Journal of Neuropsychopharmacology|December 10, 2015
Neurobiological Insights from mGlu Receptor Allosteric ModulationDaniel E O'Brien, P Jeffrey Conn
ACS Chemical Neuroscience|October 23, 2018
Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent ModelsSamantha E Yohn, P Jeffrey Conn
Pharmacological Reviews|June 16, 2022
Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric DiseaseDeborah J Luessen, P Jeffrey Conn
Neuropharmacology|September 13, 2017
Positive allosteric modulation of M<sub>1</sub> and M<sub>4</sub> muscarinic receptors as potential therapeutic treatments for schizophreniaSamantha E Yohn, P Jeffrey Conn
Neuropharmacology|July 16, 2008
Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cellsDouglas J Sheffler, P Jeffrey Conn
Pageof 42